This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • LUX-Head & Neck 2. A randomised, double-blind, pla...
Clinical trial

LUX-Head & Neck 2. A randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemoradiotherapy in primary unresected patients with stage III, IVa, or IVb loco-regi

Read time: 1 mins
Last updated:27th Jun 2011
To investigate the efficacy and safety of afatinib compared to placebo as adjuvant therapy after chemo-radiotherapy in patients with loco-regionally advanced head and neck squamous cell carcinoma. Efficacy will be measured by comparing Disease Free Survival (DFS) between the two arms.
Category Value
Study start date 2011-06-27

View full details